Novavax | Sustainability Performance
Develops vaccines and immunization technologies intended for infectious diseases. Its operations include clinical trials, regulatory approvals, and partnerships to manufacture and distribute vaccine products at scale.
1987
United States
501 - 1,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8723
Overallⓘ#1998
in United Statesⓘ#211
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Novavax Inc, US COVID19 vaccine (Nuvaxovid), has faced multiple US shareholder class actions over alleged inadequate disclosure of COVID vaccine customer demand collapse following the broader 20232024 COVID vaccine market normalization, plus periodic SEC enforcement scrutiny over alleged inadequate disclosure of manufacturing capacity buildouts affecting US institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
1
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.